Precision BioSciences在美国基因与细胞疗法学会第23届年会上发表

StephenW

Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
Article

DURHAM, NC, April 28, 2020 (GLOBE NEWSWIRE)-Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.

"The abstracts being presented by Precision and our collaborators this year at ASGCT underscore the differentiated capabilities of our proprietary ARCUS genome editing platform and the breadth of our emerging pipeline applying this technology in vivo," commented Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. “These presentations demonstrate the specificity and versatility of ARCUS-driven genome editing in a variety of large animal models and provide further preclinical evidence of potentially meaningful and durable therapeutic impact on a range of genetic and infectious diseases. As we continue to validate ARCUS 'potential in vivo, we are focused on advancing our gene correction pipeline. We look forward to selecting a clinical candidate for our wholly owned PH1 program, expected in 2020, and, in partnership with Gilead, developing a potential cure for chronic hepatitis B infection, for which submission of an IND is currently targeted for 2021.

Precision BioSciences Presentations:

Title: Engineering a Self-Inactivating Adeno-Associated Virus (AAV) Vector for ARCUS Nuclease Delivery
Poster Session: Gene Targeting and Gene Correction, Abstract: 654
Presenting Author: Hui Li, Ph.D., Precision BioSciences

Title: A Gene Editing Approach to Eliminate Hepatitis B Virus Using ARCUS Meganucleases
Poster Session: Gene Targeting and Gene Correction, Abstract 1057
Presenting Author: Cassie Gorsuch, Ph.D., Precision BioSciences

Partnered Presentations:

Title: Therapeutic Efficacy of ARCUS Meganuclease Gene Editing-Arrest of Rod Degeneration and Restoration of Rod Function in a Transgenic Pig Model of Autosomal Dominant Retinitis Pigmentosa
Oral Presentation: Gene Therapy for the Special Senses, Abstract 2
Date / Time: Tuesday, May 12, 2020, 10:30 – 10:45 a.m. EST
Presenting Author: Maureen Ann McCall, Ph.D., Professor, Department of Ophthalmology and Visual Sciences, University of Louisville

Title: Evaluation of the Long-term Effects of AAV-Meganuclease Genome Editing of PCSK9 in Macaque Liver
Oral Presentation: Evaluating Genome Editing Activity and Precision, Abstract 518
Date / Time: Wednesday, May 13, 2020, 4:00 – 4:15 p.m. EST
Presenting Author: Lili Wang, Ph.D., Research Director, Discovery Research and Gene Editing, Research Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania

All abstracts for the ASGCT 2020 Meeting are available online at ASGCT Annual Meeting Abstracts.

About Precision BioSciences, Inc.
Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, "ARCUS." Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visit www.precisionbiosciences.com.

StephenW

Precision BioSciences在美国基因与细胞疗法学会第23届年会上发表演讲
文章

2020年4月28日，北卡罗来纳州杜伦市-全球领先的生命科学公司Precision BioSciences，Inc.（纳斯达克股票代码：DTIL）致力于通过应用其开创性的专有ARCUS®基因编辑平台来改善生活。公司及其合作伙伴将出席即将于2020年5月12日至15日举行的美国遗传与细胞治疗学会（ASGCT）年度会议。

“ Precision和我们的合作伙伴今年在ASGCT上展示的摘要强调了我们专有的ARCUS基因组编辑平台的差异化功能以及我们在体内应用该技术的新兴管道的广度，”首席科学官兼联合创始人Derek Jantz评论道。精密生物科学学院。 “这些演讲证明了ARCUS驱动的基因组编辑在各种大型动物模型中的特异性和多功能性，并提供了进一步的临床前证据，证明其对一系列遗传和传染病具有潜在的有意义和持久的治疗影响。随着我们继续验证ARCUS在体内的潜力，我们专注于推进基因校正流程。我们期待为我们的全资PH1计划选择临床候选药物，预计在2020年进行，并与吉利德（Gilead）合作开发治疗慢性乙型肝炎的潜在方法，目前计划于2021年提交IND。

精密生物科学演示：

标题：设计用于ARCUS核酸酶递送的自灭活腺相关病毒（AAV）载体
张贴者会议：基因靶向和基因校正，摘要：654
演讲人：李慧，精密生物科学博士

发言题目：使用ARCUS大范围核酸酶消除乙型肝炎病毒的基因编辑方法
张贴者会议：基因靶向和基因校正，摘要1057
演讲人：精确生物科学博士Cassie Gorsuch

合作演示：

发言题目：在常染色体显性遗传性视网膜色素变性的转基因猪模型中，ARCUS大范围核酸酶基因编辑抑制杆变性和杆功能恢复的治疗功效
口头报告：特殊感觉的基因治疗，摘要2
日期/时间：美国东部时间2020年5月12日，星期二，上午10:30 – 10:45
报告作者：莫琳·安·麦考尔（Maureen Ann McCall）博士，路易斯维尔大学眼科学和视觉科学系教授

发言题目：评价猕猴肝脏中PCSK9的AAV-核酸内切酶基因组编辑的长期效果
口头报告：评估基因组编辑活性和准确性，摘要518
日期/时间：2020年5月13日，星期三，下午4:00 – 4:15美东时间
主讲人：王丽丽博士，宾夕法尼亚大学佩雷​​尔曼医学院医学系研究副教授，发现研究和基因编辑

ASGCT 2020会议的所有摘要均可在ASGCT年度会议摘要中在线获得。

关于Precision BioSciences，Inc.
Precision BioSciences通过其专有的基因组编辑平台“ ARCUS”致力于改善生活（DTIL）。 Precision利用ARCUS开发其候选产品，这些产品旨在治疗人类疾病并创造健康，可持续的食品和农业解决方案。 Precision正在三个创新领域积极开发候选产品：同种异体CAR T免疫疗法，体内基因校正和食品。有关Precision的更多信息，请访问www.precisionbiosciences.com。